Chronic metabolic acidosis
Methodology & AI Transparency ⓘ
Chronic metabolic acidosis Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: Recognized across U.S.
- 2 Real-world patient consensus: Diagnostic registry E87.22: Chronic metabolic acidosis is managed within Kidney & Renal.
- 3 Typical cash cost range: Primary evaluation for Chronic metabolic acidosis incorporates serial eGFR (creatinine in Chronic metabolic acidosis (E87.22: + cystatin C)) and symptom diary review.
- 4 Top reported side effects / signs: Follow-up benchmark in Chronic metabolic acidosis: maintaining Serum Potassium, Bicarbonate in Chronic metabolic acidosis (E87.22: & Phosphorus) within K+ 3.8–4.8 mEq/L; HCO3 23–29 mEq/L (E87.22).
Ask our AI Specialists anything about Chronic metabolic acidosis
What Is Chronic metabolic acidosis?
Recognized across U.S. clinical coding as E87.22 (Kidney & Renal), Chronic metabolic acidosis is evaluated via serial eGFR (creatinine in Chronic metabolic acidosis (E87.22: + cystatin C)) to align day-to-day symptom relief with long-term physiological stability.
Pathophysiology, Underlying Causes & Clinical Presentation
Underlying Chronic metabolic acidosis (code E87.22) is disordered calcium-phosphate-PTH mineral in Chronic metabolic acidosis (E87.22: metabolism), which Chronic Kidney Disease & Electrolytes clinicians address while surveilling Serum Potassium, Bicarbonate in Chronic metabolic acidosis (E87.22: & Phosphorus) (K+ 3.8–4.8 mEq/L; HCO3 23–29 mEq/L (E87.22)).
Common Symptoms & Clinical Signs
- • Presentation of Chronic metabolic acidosis (E87.22): fluid retention in in Chronic metabolic acidosis (E87.22: ankles, hands, or)
- • Secondary Chronic metabolic acidosis clinical sign: fatigue, muscle cramps, in Chronic metabolic acidosis (E87.22: metallic taste, or)
- • Symptom flares in Chronic metabolic acidosis correlating with Serum Potassium, Bicarbonate in Chronic metabolic acidosis (E87.22: & Phosphorus) deviation outside K+ 3.8–4.8 mEq/L; HCO3 23–29 mEq/L (E87.22)
- • Functional kidney & renal impact requiring serial eGFR (creatinine in Chronic metabolic acidosis (E87.22: + cystatin C)) evaluation (E87.22)
Chronic metabolic acidosis Diagnostic Classification & Lab Markers
| Metric | Verified Benchmark | Source |
|---|---|---|
| ICD-10-CM Diagnostic Code | E87.22 | WHO / CMS ICD-10-CM Clinical Classification |
| Clinical Specialty Hub | Chronic Kidney Disease & Electrolytes | NLM Clinical Tables |
| Diagnostic / Lab Marker: Serum Potassium, Bicarbonate in Chronic metabolic acidosis (E87.22: & Phosphorus) | K+ 3.8–4.8 mEq/L; HCO3 23–29 mEq/L (E87.22) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: eGFR (Creatinine + in Chronic metabolic acidosis (E87.22: Cystatin C)) | >= 90 mL/min/1.73m2 (E87.22) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Urine Albumin-to-Creatinine Ratio in Chronic metabolic acidosis (E87.22: (uACR)) | < 15 mg/g (< 30 mg/g normal) (E87.22) | Clinical Reference Target Range |
FDA-Monographed Medications & Public Cash Price Reference for Chronic metabolic acidosis
Treatment selection for Chronic metabolic acidosis depends on clinical severity, diagnostic lab results, and medical history. Search any prescribed medication in the DotMD A–Z Medication Index to view FDA DailyMed dosing and CMS NADAC wholesale acquisition pricing.
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Chronic metabolic acidosis)
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| New Insights on Safety and real-world benefits of Semaglutide in Patients With Chronic Kidney: What a 12,785-Participant Study Found Semaglutide demonstrates a favourable safety profile and significant cardiorenal benefits in CKD patients, with or without T2DM. Endocrinology, diabetes & metabolism • 2025-11-15 • Meta-Analysis | N = 12,785 | 99/100 | PMID 41276951 ↗ |
| New Insights on Individual Atrasentan Exposure is Associated With Long-term Kidney and Heart: What a 3,668-Participant Study Found Compared with placebo, a mean atrasentan exposure translated in a hazard ratio of 0.76 (95% confidence interval (CI): 0.28-0.85) for kidney events and 1.13 (95% CI: 1.03-2.20) for heart failure events. Clinical pharmacology and therapeutics • 2021-06-15 • Phase III Randomized Trial | N = 3,668 | 96/100 | PMID 33338269 ↗ |
| New Insights on Reductions in acute medication use and healthcare resource utilization in: What a 1,113-Participant Study Found Treatment with galcanezumab resulted in significant reductions in headache medication overuse and migraine headache days requiring acute medication use, with notable reductions in migraine-specific HCRU. Journal of medical economics • 2022-01-15 • Phase III Randomized Trial | N = 1,113 | 96/100 | PMID 35971655 ↗ |
| New Insights on Empagliflozin Reduces Risk of Hospitalization in Patients With Chronic Kidney: What a 6,609-Participant Study Found 1995 participants (1035 placebo, 960 empagliflozin) had ≥1 ACH (1895 ACH in placebo and 1611 in the empagliflozin 10-mg groups). Clinical therapeutics • 2025-12-15 • Phase III Randomized Trial | N = 6,609 | 96/100 | PMID 41047325 ↗ |
| New Insights on Treatment of chronic migraine with Botox (onabotulinumtoxinA): Development,: What a 5,000-Participant Study Found Benefits also include improvements in quality of life, fewer psychiatric comorbidities, and reduced healthcare resource utilization. Medicine • 2023-07-01 • Phase III Randomized Trial | N = 5,000 | 96/100 | PMID 37499085 ↗ |
Chronic metabolic acidosis Patient Community & “People Like Me” Threads
Filter Chronic metabolic acidosis community threads and patient logs by age, biological sex, dosage, and treatment duration.